NK/T-cell lymphomas 'nasal type': An Italian multicentric retrospective survey

Annals of Oncology

Volumn 17, Issue 5, 2006, Pages 794-800

  Pagano, L ^a   Gallamini, A ^b   Trape G ^a,c   Fianchi, L ^a   Mattei, D ^b   Todeschini, G ^d   Spadea, A ^e   Cinieri, S ^f   Iannitto, E ^g   Martelli, M ^h   Nosari, A ⁱ   Di Bona, E ^j   Tosti, M E ^k   Petti, M C ^e   Falcucci, P ^a   Montanaro, M ^c   Pulsoni, A ^h   Larocca, L M ^a   Leone, G ^a  

^a CATHOLIC UNIVERSITY   (Italy)

^b Ospedale di Cuneo   (Italy)

^c Ospedale di Montefiascone   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e REGINA ELENA NATIONAL CANCER INSTITUTE   (Italy)

^f EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^g UNIVERSITY OF PALERMO   (Italy)

^h SAPIENZA UNIVERSITY OF ROME   (Italy)

ⁱ OSPEDALE NIGUARDA CA GRANDA   (Italy)

^j Ospedale di Vicenza   (Italy)

^k ISTITUTO SUPERIORE DI SANITÀ   (Italy)

more..

Author keywords

Lymphoma treatment; NK T cell

Indexed keywords

ANTHRACYCLINE DERIVATIVE; BLEOMYCIN; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FOLINIC ACID; METHOTREXATE; MITOXANTRONE; PREDNISONE; VINCRISTINE SULFATE;

ADULT; AGED; ARTICLE; BONE MARROW METASTASIS; CANCER STAGING; CANCER SURVIVAL; CAUCASIAN; CLINICAL ARTICLE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE FREE SURVIVAL; FEMALE; HISTOPATHOLOGY; HUMAN; IMMUNOPHENOTYPING; ITALY; LYMPH NODE METASTASIS; MALE; NASOPHARYNX CANCER; NATURAL KILLER CELL; NOSE CANCER; OROPHARYNX CANCER; PRIORITY JOURNAL; PROGNOSIS; REMISSION; RETROSPECTIVE STUDY; SKIN DEFECT; SYMPTOM; T CELL LYMPHOMA; TREATMENT FAILURE;

EID: 33646184877     PISSN: 09237534     EISSN: 15698041     Source Type: Journal    
DOI: 10.1093/annonc/mdl015     Document Type: Article

References (39)

1. Ribrag V, Ell Hajj M, Janot F et al. Early locoregional high-dose radiotherapy is associated with long-term disease control in localized primary angiocentric lymphoma of the nose and nasopharynx. Leukemia 2001; 15: 1123-1126.
2. Santucci M, Pimpinelli N, Massi D et al. Cytotoxic/natural killer cell cutaneous lymphomas. Report of EORTC Cutaneous Lymphoma Task Force Workshop. Cancer 2003; 97: 610-627.
3. Mraz-Gernhard S, Natkunam Y, Hoppe RT et al. Natural killer/natural killer-like T-cell lymphoma, CD56+, presenting in the skin: An increasingly recognized entity with an aggressive course. J Clin Oncol 2001; 19: 2179-2188.
4. Bekkenk MW, Jansen PM, Meijer CJ, Willemze R. CD56+ hematological neoplasms presenting in the skin: A retrospective analysis of 23 new cases and 130 cases from the literature. Ann Oncol 2004; 15: 1097-1108.
5. Rudiger T, Weisenburger DD, Anderson JR et al. Peripheral T-cell lymphoma (excluding anaplastic large-cell lymphoma): Results from the Non-Hodgkin's Lymphoma Classification Project. Ann Oncol 2002; 13: 140-149.
6. Garcia-Cosio M, Santon A, Mendez MC et al. Nasopharyngeal/nasal type T/ NK lymphomas: Analysis of 14 cases and review of the literature. Tumori 2003; 89: 278-284.
7. Chan JKC, Jaffe ES, Ralfkiaer E. Extranodal NK/T-cell lymphoma, nasal type, in 'Pathology and Genetics. Tumors of hematopoietic and lymphoid tissue', IARC 2001, 204-207.
8. Jaffe ES, Krenacs L, Raffeld M. Classification of cytotoxic T-cell and natural killer cell lymphomas. Semin Hematol 2003; 40: 175-184.
9. Harris NL, Jaffe ES, Diebold J et al. The World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues. Report of the Clinical Advisory Committee meeting, Airlie House, Virginia, November, 1997. Ann Oncol 1999; 10: 1419-1432.
10. Cheung MM, Chan JK, Lau WH et al. Early stage nasal NK/T-cell lymphoma: clinical outcome, prognostic factors, and the effect of treatment modality. Int J Radiat Oncol Biol Phys 2002; 54: 182-190.
11. Kim WS, Song SY, Ahn YC et al. CHOP followed by involved field radiation: Is it optimal for localized nasal natural killer/T-cell lymphoma? Ann Oncol 2001; 12: 349-352.
12. Kwong YL, Chan ACL, Liang R et al. CD 56+ NK lymphomas: clinicopathological features and prognosis. Br J Haematol 1997; 97: 821-829.
13. Li CC, Tien HF, Tang JL et al. Treatment outcome and pattern of failure in 77 patients with sinonasal natural killer/T-cell or T-cell lymphoma. Cancer 2004; 100: 366-375.
14. Nakamura S, Katoh E, Koshikawa T et al. Clinicopathologic study of nasal T/NK-cell lymphoma among the Japanese. Pathol Int 1997; 47: 38-53.
15. Sakata K, Hareyama M, Ohuchi A et al. Treatment of lethal midline granuloma type nasal T-cell lymphoma. Acta Oncol 1997; 36: 307-311.
16. Seki D, Ueno K, Kurono Y, Eizuru Y. Clinicopathological features of Epstein-Barr virus associated nasal T/NK cell lymphomas in southern Japan. Auris Nasus Larynx 2001; 28: 61-70.
17. Chim CS, Ma SY, Au WY et al. Primary nasal natural killer cell lymphoma: long-term treatment outcome and relationship with the International Prognostic Index. Blood 2004: 103: 216-221.
18. Ko YH, Cho EY, Kim JE et al. NK and NK-like T-cell lymphoma in extranasal sites: A comparative clinicopathological study according to site and EBV status. Histopathology 2004; 44: 480-489.
19. Lee J, Kim WS, Park YH et al. Nasal-type NK/T cell lymphoma: Clinical features and treatment outcome. Br J Cancer 2005; 92: 1226-1230.
20. Kim BS, Kim TY, Kim CW et al. Therapeutic outcome of extranodal NK/ T-cell lymphoma initially treated with chemotherapy-result of chemotherapy in NK/T-cell lymphoma. Acta Oncol 2003; 42: 779-783.
21. Aviles A, Diaz NR, Neri N et al. Angiocentric nasal T/natural killer cell lymphoma: A single centre study of prognostic factors in 108 patients. Clin Lab Haematol 2000; 22: 215-220.
22. Rodriguez J, Romaguera JE, Manning J et al. Nasal-type T/NK lymphomas: A clinicopathologic study of 13 cases. Leuk Lymphoma 2000; 39: 139-144.
23. Aviles A, Neri N, Fernandez R et al. Nasal NK/T-cell lymphoma with disseminated disease treated with aggressive combined therapy. Med Oncol 2003; 20: 13-17.
24. Quintanilla-Martinez L, Kremer M, Keller G et al. p53 Mutations in nasal natural killer/T-cell lymphoma from Mexico: Association with large cell morphology and advanced disease. Am J Pathol 2001; 159: 2095-2105.
25. The International non-Hodgkin's Lymphoma Prognostic factrors project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993; 329: 987-994.
26. Larocca LM, Capello D, Rinelli A et al. The molecular and phenotypic profile of central nervous system lymphoma identifies distinct categories of the disease and is consistent with histogenetic derivation from germinal center-treated B cells. Blood 1998: 92: 1011-1019.
27. You Y, Chi KH, Yang MH et al. Radiation therapy versus chemotherapy as initial treatment for localized nasal natural killer (NK)/T-cell lymphoma: A single institute survey in Taiwan. Ann Oncol 2004; 15: 618-625.
28. Kim K, Chie EK, Kim CW et al. Treatment outcome of angiocentric T-cell and NK/T-cell lymphoma, nasal type: Radiotherapy versus chemoradiotherapy. Jpn J Clin Oncol 2005; 35: 1-5.
29. Kuo TT, Shih LY, Tsang NM. Nasal NK/T cell lymphoma in Taiwan: A clinicopathologic study of 22 cases, with analysis of histologic subtypes, Epstein-Barr virus LMP-1 gene association, and treatment modalities. Int J Surg Pathol 2004; 12: 375-387.
30. Isogai R, Kawada A, Hashimoto K et al. Nasal-type NK/T-cell lymphoma successfully treated with ProMACE-CytaBOM therapy. Dermatology 2004; 209: 243-5.
31. Matsumoto Y, Nomura K, Kanda-Akano Y et al. Successful treatment with Erwinia L-asparaginase for recurrent natural killer/T cell lymphoma. Leuk Lymphoma 2003; 44: 879-882.
32. Nomura E, Isoda K, Yamanaka K et al. Extra nodal NK/T-cell lymphoma nasal type that responded to DeVIC combination chemotherapy. J Dermatol 2005; 32: 204-209.
33. Takenaka K, Shinagawa K, Maeda Y et al. High-dose chemotherapy with hematopoietic stem cell transplantation is effective for nasal and nasal-type CD56+ natural killer cell lymphomas. Leuk Lymphoma 2001; 42: 1297-1303.
34. Gallamini A, Stelitano C, Calvi R et al. Peripheral T-cell lymphoma unspecified (PTCL-U): A new prognostic model from a retrospective multicentric clinical study. Blood 2004; 103: 2474-2479.
35. Gutierrez A, Rodriguez J, Ramos R et al. Treatment with alemtuzumab in a case of refractory primary cutaneous CD30-negative CD8-positive cytotoxic large T-cell lymphoma. Eur J Haematol 2004; 72: 377-378.
36. Lundin J, Hagberg H, Repp R et al. Phase 2 study of alentuzumab (anti-CD52 monoclonal antibody) in patients with advanced mycosis fungoides/Sezary syndrome. Blood 2003; 101: 4267-4272.
37. Au WY, Lie AK, Liang R, Kwong YL, Yau CC, Cheung MM et al. Autologous stem cell transplantation for nasal NK/T-cell lymphoma: A progress report on its value. Ann Oncol 2003; 14: 1673-1676.
38. Okamura T, Kishimoto T, Inoue M et al. Unrelated bone marrow transplantation for Epstein-Barr virus-associated T/NK-cell lymphoproliferative disease. Bone Marrow Transplant 2003 Jan; 31(2): 105-111.
39. Murashige N, Kami M, Kishi Y, Kim SW, Takeuchi M, Matsue K et al. Allogeneic haematopoietic stem cell transplantation as a promising treatment for natural killer-cell neoplasms. Br J Haematol 2005; 150: 561-567.